We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bosutinib in Adult Patients With Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01331291
Recruitment Status : Completed
First Posted : April 8, 2011
Results First Posted : June 20, 2016
Last Update Posted : July 25, 2016
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Glioblastoma
Intervention: Drug: bosutinib

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Arm A

Patients who are surgical candidates

bosutinib: Taken orally

Arm B

Patients that are not surgical candidates

bosutinib: Taken orally


Participant Flow:   Overall Study
    Arm A   Arm B
STARTED   2   9 
COMPLETED   0   0 
NOT COMPLETED   2   9 
Lack of Efficacy                2                8 
Death                0                1 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Arm A

Patients who are surgical candidates

bosutinib: Taken orally

Arm B

Patients that are not surgical candidates

bosutinib: Taken orally

Total Total of all reporting groups

Baseline Measures
   Arm A   Arm B   Total 
Overall Participants Analyzed 
[Units: Participants]
 2   9   11 
Age 
[Units: Years]
Median (Full Range)
 60 
 (58 to 62) 
 44 
 (36 to 62) 
 52 
 (36 to 62) 
Gender 
[Units: Participants]
     
Female   0   4   4 
Male   2   5   7 
Prior Surgery [1] 
[Units: Participants]
     
Gross Total Resection   1   6   7 
Sub total Resection   0   3   3 
No prior surgery   1   0   1 
[1] Surgery done at time of diagnosis with glioblastoma
Karnofsky Performance Status (KPS) [1] 
[Units: Units on a scale]
Median (Full Range)
 80 
 (70 to 90) 
 90 
 (70 to 90) 
 90 
 (70 to 90) 
[1] A standard way of measuring the ability of cancer patients to perform ordinary tasks. The Karnofsky Performance Status scores range from 0 to 100. A higher score means the patient is better able to carry out daily activities. (0 being 'Dead' and 100 being 'Normal, no complaints; no evidence of disease'.)
Prior chemoradiation [1] 
[Units: Participants]
 2   9   11 
[1] Number of patients who previously received standard, initial therapy with temozolomide and radiation at diagnosis


  Outcome Measures

1.  Primary:   Progression-Free Survival   [ Time Frame: 2 years ]

2.  Secondary:   Intratumoral Concentration   [ Time Frame: 2 years ]

3.  Secondary:   Safety Profile   [ Time Frame: 2 years ]

4.  Secondary:   Anti-tumor Response   [ Time Frame: 2 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
This study met pre-specified criteria for early closure, as all 9 patients enrolled on Arm B demonstrated disease progression within 6 months.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Tracy T. Batchelor, MD
Organization: Massachusetts General Hospital
phone: 617-643-1938
e-mail: tbatchelor@mgh.harvard.edu


Publications:

Responsible Party: Tracy T. Batchelor, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01331291     History of Changes
Other Study ID Numbers: 10-190
First Submitted: March 28, 2011
First Posted: April 8, 2011
Results First Submitted: June 9, 2016
Results First Posted: June 20, 2016
Last Update Posted: July 25, 2016